- Medical School - Touro College of Osteopathic Medicine (2014-2018)
- Residency - UT Southwestern Medical Center (2018-2020), Internal Medicine
- Fellowship - UT Southwestern Medical Center (2020-2024), Hematology Oncology
Jake Lichterman, D.O.
- Internal Medicine - Hematology/Oncology
- Genitourinary Malignancies
- Kidney Cancer
Biography
Jake Lichterman, D.O., is an Instructor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in the treatment of genitourinary malignancies and has a special interest in kidney and bladder cancer.
Dr. Lichterman holds an undergraduate degree from the University of California Los Angeles. He earned his medical degree at Touro College of Osteopathic Medicine in New York. He completed a residency in internal medicine and received advanced training through a hematology and oncology fellowship at UT Southwestern, where he was part of the Physician Scientist Training Program.
Certified by the American Board of Internal Medicine, he joined the UT Southwestern faculty in 2024.
Dr. Lichterman is a physician-scientist whose laboratory and translational research focuses on the circadian clock and cancer immunotherapy. His long-term goal is to improve outcomes for cancer patients through immunotherapy, which holds curative potential. He has delivered presentations and published academic articles related to his areas of expertise.
Personal Note
When he’s not at work, Dr. Lichterman enjoys spending time with his family, exploring new cultures through travel and food, and supporting his favorite basketball team, the Los Angeles Lakers.
Education & Training
Professional Associations & Affiliations
- Society for Immunotherapy of Cancer
- American Association for Cancer Research
Books & Publications
-
Publications
-
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A, Lichterman JN, Zhong JY, Shoag JE, Garcia JA, Zhang T, Barata PC, Human vaccines & immunotherapeutics 2023 Dec 19 3 2276629 -
Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity.
Choi Y, Lichterman JN, Coughlin LA, Poulides N, Li W, Del Valle P, Palmer SN, Gan S, Kim J, Zhan X, Gao Y, Evers BM, Hooper LV, Pasare C, Koh AY, Science immunology 2023 Mar 8 81 eabo2003 -
Mast Cells: A New Frontier for Cancer Immunotherapy.
Lichterman JN, Reddy SM, Cells 2021 May 10 6 -
A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, Posadas EM Oncotarget 2015 Nov -
Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.
Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, Hou S, Ahmed RS, Luthringer DJ, Huang J, Li KC, Chung LW, Ke Z, Tseng HR, Posadas EM Cancer 2015 May -
miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer.
Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW, Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Dec 20 24 6559-69 -
miR-409-3p/-5p promotes tumorigenesis, epithelial to mesenchymal transition and bone metastasis of human prostate cancer.
Josson S, Gururajan M, Hu P, Shao C, Chu CY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Jun -
NanoVelcro Chip for CTC enumeration in prostate cancer patients.
Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM, Methods (San Diego, Calif.) 2013 Dec 64 2 144-52
-
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Research
- Cancer immunotherapy
- Circadian rhythms
- Gut microbiota
- Genitourinary malignancies
Clinical Focus
- Genitourinary Malignancies
- Kidney Cancer
- Bladder Cancer